NovoCure Ltd (NASDAQ: NVCR) on Monday, soared 4.30% from the previous trading day, before settling in for the closing price of $17.44. Within the past 52 weeks, NVCR’s price has moved between $10.87 and $24.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 17.16%. The company achieved an average annual earnings per share of 32.97%. With a float of $97.35 million, this company’s outstanding shares have now reached $107.08 million.
Considering the fact that the conglomerate employs 1453 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 76.41%, operating margin of -27.51%, and the pretax margin is -19.82%.
NovoCure Ltd (NVCR) Insider Activity
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of NovoCure Ltd is 10.03%, while institutional ownership is 87.50%. The most recent insider transaction that took place on Nov 02 ’24, was worth 734. In this transaction Chief Operating Officer of this company sold 44 shares at a rate of $16.69, taking the stock ownership to the 3,459 shares. Before that another transaction happened on Oct 31 ’24, when Company’s Chief Human Resources Officer sold 810 for $15.79, making the entire transaction worth $12,792. This insider now owns 110,093 shares in total.
NovoCure Ltd (NVCR) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.45 earnings per share (EPS) for the period topping the consensus outlook (set at -0.52) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 32.97% per share during the next fiscal year.
NovoCure Ltd (NASDAQ: NVCR) Trading Performance Indicators
NovoCure Ltd (NVCR) is currently performing well based on its current performance indicators. A quick ratio of 1.44 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.39, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.58 in one year’s time.
Technical Analysis of NovoCure Ltd (NVCR)
Compared to the last year’s volume of 1.3 million, its volume of 0.97 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 76.07%. Additionally, its Average True Range was 1.16.
During the past 100 days, NovoCure Ltd’s (NVCR) raw stochastic average was set at 41.44%, which indicates a significant decrease from 86.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.75% in the past 14 days, which was higher than the 66.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.56, while its 200-day Moving Average is $17.02. Nevertheless, the first resistance level for the watch stands at $18.41 in the near term. At $18.63, the stock is likely to face the second major resistance level. The third major resistance level sits at $19.05. If the price goes on to break the first support level at $17.77, it is likely to go to the next support level at $17.35. Should the price break the second support level, the third support level stands at $17.13.
NovoCure Ltd (NASDAQ: NVCR) Key Stats
Market capitalization of the company is 1.94 billion based on 108,201K outstanding shares. Right now, sales total 509,340 K and income totals -207,040 K. The company made 155,100 K in profit during its latest quarter, and -30,570 K in sales during its previous quarter.